Plus Therapeutics, Inc.
PSTV
$5.50
-$0.03-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.18M | 5.21M | 5.26M | 5.32M | 5.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.18M | 5.21M | 5.26M | 5.32M | 5.21M |
| Cost of Revenue | 9.49M | 8.38M | 7.62M | 8.05M | 9.57M |
| Gross Profit | -4.31M | -3.17M | -2.37M | -2.73M | -4.37M |
| SG&A Expenses | 14.58M | 12.13M | 11.09M | 10.04M | 10.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.06M | 20.51M | 18.71M | 18.09M | 20.14M |
| Operating Income | -18.88M | -15.30M | -13.46M | -12.77M | -14.93M |
| Income Before Tax | -11.93M | -22.39M | -20.58M | -19.03M | -27.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.93 | -22.39 | -20.58 | -19.03 | -27.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.93M | -22.39M | -20.58M | -19.03M | -27.12M |
| EBIT | -18.88M | -15.30M | -13.46M | -12.77M | -14.93M |
| EBITDA | -18.49M | -14.85M | -12.81M | -12.00M | -14.07M |
| EPS Basic | -2.50 | -31.32 | -42.69 | -50.80 | -62.72 |
| Normalized Basic EPS | -0.28 | -18.29 | -25.40 | -30.47 | -39.20 |
| EPS Diluted | -3.29 | -32.11 | -43.46 | -51.68 | -69.29 |
| Normalized Diluted EPS | -1.56 | -19.57 | -26.68 | -31.75 | -36.41 |
| Average Basic Shares Outstanding | 18.39M | 12.32M | 7.13M | 3.15M | 1.47M |
| Average Diluted Shares Outstanding | 24.82M | 18.75M | 13.56M | 9.58M | 1.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |